Biotech Stock Intel
Catalyst CalendarPDUFA CalendarMover SignalsCompany Screener
Disclaimer: Biotech Stock Intel is an independent research platform. Information is provided for informational purposes only and is not investment or medical advice. Always verify catalyst dates against primary sources and conduct your own research.
Biotech Stock Intel© 2026 Biotech Stock Intel
AboutMethodologyTermsPrivacy
Biotech Stock Intel
Catalyst CalendarPDUFA CalendarMover SignalsCompany Screener
Home/Stocks/QURE/Catalyst
Phase 1/2Data readout

AMT-260

Mesial temporal lobe epilepsy (MTLE)

QUREUniqure NV
Expected catalystJune 30, 2027Company guidance: Jun 30, 2027

Catalyst overview

Event details

Drug or asset
AMT-260
Development stage
Phase 1/2
Event type
Data readout
Indication
Mesial temporal lobe epilepsy (MTLE)

Research summary

What is being tracked?

This catalyst tracks a Phase 1/2 data readout for AMT-260 in Mesial temporal lobe epilepsy (MTLE). The expected timing is based on the latest available company guidance and may change.

Development notes

07/29/26:- First-cohort data reported; second cohort completion Q3 2026; updated Ph1/2a results H1 2027.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Open source

More from QURE

Related pipeline programs

Phase 1/2

AMT-191

Fabry disease

View company pipeline
Failed

AMT-162

Amyotrophic lateral sclerosis

View company pipeline

Company

Uniqure NV

QURE · NasdaqGS
Industry
Biotechnology
Pipeline assets
5
View QURE research

BioPharma Pro

Track every date change

Watchlists, source history and catalyst alerts will be available with Pro.

Start free

Updated Aug 23, 2026. Dates can change; this is not investment advice.

Disclaimer: Biotech Stock Intel is an independent research platform. Information is provided for informational purposes only and is not investment or medical advice. Always verify catalyst dates against primary sources and conduct your own research.
Biotech Stock Intel© 2026 Biotech Stock Intel
AboutMethodologyTermsPrivacy